echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Endocrine System > Cardiovasc Diabetol: Changes in metformin and high-sensitivity cardiac troponin I and T in patients with type 2 diabetes

    Cardiovasc Diabetol: Changes in metformin and high-sensitivity cardiac troponin I and T in patients with type 2 diabetes

    • Last Update: 2022-05-13
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Background: Although metformin has been used as a first-line pharmacological approach for over 60 years to moderate hyperglycemia and increase insulin sensitivity, its pleiotropic benefits in reducing complications from type 2 diabetes and the general aging process continue to attract Doctors and scientific researchers from a range of disciplines
    .
    Previously reported results from the UK Prospective Diabetes Study and the Home Trial indicated that metformin had favorable effects on cardiovascular outcomes in patients with both newly diagnosed and advanced type 2 diabetes
    .
    Patients with type 2 diabetes have chronically elevated levels of circulating cardiac troponin, an established predictor of cardiovascular endpoints and a prognostic marker of subclinical myocardial injury

    .
    It is not known whether metformin affects cardiac troponin levels
    .
    This study was designed to assess changes in cardiac troponin I and T in diabetic patients receiving metformin or placebo

    .

    Background: Although metformin has been used as a first-line pharmacological approach for over 60 years to moderate hyperglycemia and increase insulin sensitivity, its pleiotropic benefits in reducing complications from type 2 diabetes and the general aging process continue to attract Doctors and scientific researchers from a range of disciplines
    .
    Previously reported results from the UK Prospective Diabetes Study and the Home Trial indicated that metformin had favorable effects on cardiovascular outcomes in patients with both newly diagnosed and advanced type 2 diabetes
    .
    Patients with type 2 diabetes have chronically elevated levels of circulating cardiac troponin, an established predictor of cardiovascular endpoints and a prognostic marker of subclinical myocardial injury

    .
    It is not known whether metformin affects cardiac troponin levels
    .
    This study was designed to assess changes in cardiac troponin I and T in diabetic patients receiving metformin or placebo

    .
    Although metformin has been used as a first-line pharmacological approach for over 60 years to moderate hyperglycemia and increase insulin sensitivity, previously reported results from the UK Prospective Diabetes Study and a home trial suggest that metformin is effective in both new and advanced type 2 diabetes.
    Cardiovascular outcomes had favorable outcomes

    .
    Patients with type 2 diabetes have chronically elevated levels of circulating cardiac troponin, an established predictor of cardiovascular endpoints and a prognostic marker of subclinical myocardial injury

    .

    Methods: This study was a post hoc analysis of a randomized controlled trial (HOME trial) that included 390 patients with advanced type 2 diabetes who were randomized to receive 850 mg of metformin or placebo up to a daily dose while continuing insulin therapy three times
    .
    Cardiac troponin I and T concentrations were measured after baseline, 4 months, 17 months, 30 months, 43 months, and 52 months, respectively

    .
    We assessed changes in cardiac troponin by linear mixed-effects modeling adjusted for age, sex, smoking status, and history of cardiovascular disease

    .

    Methods: This study was a post hoc analysis of a randomized controlled trial (HOME trial) that included 390 patients with advanced type 2 diabetes who were randomized to receive 850 mg of metformin or placebo up to a daily dose while continuing insulin therapy three times
    .
    Cardiac troponin I and T concentrations were measured after baseline, 4 months, 17 months, 30 months, 43 months, and 52 months, respectively

    .
    We assessed changes in cardiac troponin by linear mixed-effects modeling adjusted for age, sex, smoking status, and history of cardiovascular disease

    .

    Results: The study enrolled 390 subjects, of whom 196 received metformin and 194 received placebo
    .
    In the treatment and placebo groups, the mean age was 64 and 59 years, respectively; the mean age of female subjects was 50% and 58%, respectively

    .
    Although metformin was previously reported to reduce the risk of macrovascular disease in this cohort, linear mixed-effects regression models did not show evidence of an effect on cardiac troponin I and cardiac troponin T levels [−8.
    4% (−8.
    4%, respectively).
    −18.
    6, 3.
    2), p=0.
    150 and −4.
    6%(−12, 3.
    2, p=0.
    242)]

    .
    There was a statistically significant interaction between troponin T [−1.
    6% (−2.
    9, −0.
    2), p=0.
    021] and treatment time, but not with troponin I concentration [−1.
    5% (−4.
    2, 1.
    2), p =0.
    263] irrelevant

    .

    Results: The study enrolled 390 subjects, of whom 196 received metformin and 194 received placebo
    .
    In the treatment and placebo groups, the mean age was 64 and 59 years, respectively; the mean age of female subjects was 50% and 58%, respectively

    .
    Although metformin was previously reported to reduce the risk of macrovascular disease in this cohort, linear mixed-effects regression models did not show evidence of an effect on cardiac troponin I and cardiac troponin T levels [−8.
    4% (−8.
    4%, respectively).
    −18.
    6, 3.
    2), p=0.
    150 and −4.
    6%(−12, 3.
    2, p=0.
    242)]

    .
    There was a statistically significant interaction between troponin T [−1.
    6% (−2.
    9, −0.
    2), p=0.
    021] and treatment time, but not with troponin I concentration [−1.
    5% (−4.
    2, 1.
    2), p =0.
    263] irrelevant

    .

    Figure 1 Changes in cardiac troponin I (A) and T (B) with 95% confidence intervals (shaded)

    Figure 1 Changes in cardiac troponin I (A) and T (B) with 95% confidence intervals (shaded)

    Table 1 Troponin I and Troponin T—baseline, short-term (4 months), and long-term (52 ​​months) comparison (paired-samples Wilcoxon test)

    Table 1 Troponin I and Troponin T—baseline, short-term (4 months), and long-term (52 ​​months) comparison (paired-samples Wilcoxon test)

    Table 2 Random slope/random intercept model for troponin I

    Table 2 Random slope/random intercept model for troponin I

    Table 3 Random slope/random intercept model for troponin T

    Table 3 Random slope/random intercept model for troponin T

    Conclusions: In a post hoc analysis of this 4.
    3-year randomized controlled trial, metformin had no clinically relevant effect on cardiac troponin I and cardiac troponin T levels compared with placebo

    .
    The cardioprotective effects of the drug observed in clinical studies were not reflected by reductions in these biomarkers of subclinical myocardial injury

    .

    Conclusions: In a post hoc analysis of this 4.
    3-year randomized controlled trial, metformin had no clinically relevant effect on cardiac troponin I and cardiac troponin T levels compared with placebo

    .
    The cardioprotective effects of the drug observed in clinical studies were not reflected by reductions in these biomarkers of subclinical myocardial injury

    .
    In a post hoc analysis of this 4.
    3-year randomized controlled trial, metformin had no clinically relevant effect on cardiac troponin I and cardiac troponin T levels compared with placebo

    .
    The cardioprotective effects of the drug observed in clinical studies were not reflected by reductions in these biomarkers of subclinical myocardial injury

    .

    Original source: Stultiens JMG, Top WMC, Kimenai DM, et al.
    Metformin and high-sensitivity cardiac troponin I and T trajectories in type 2 diabetes patients: a post-hoc analysis of a randomized controlled trial .
    Cardiovasc Diabetol 2022 Apr 04;21 (1)

    Original source: Stultiens JMG, Top WMC, Kimenai DM, et al.
    Metformin and high-sensitivity cardiac troponin I and T trajectories in type 2 diabetes patients: a post-hoc analysis of a randomized controlled trial .
    Cardiovasc Diabetol 2022 Apr 04;21 (1) Metformin and high-sensitivity cardiac troponin I and T trajectories in type 2 diabetes patients: a
    post -hoc analysis of a randomized controlled trial

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.